IP Library Granted Patent US 11,286,236
Granted Patent B2
US 11,286,236 · App. 16/972,169 · Granted Mar 29, 2022

Compound, agent and composition for the suppression of cancer growth

Inventors: Peter Novak (Sunny Isles Beach, FL); Maxim Temnikov (Miami, FL); Oleksandr Balakin (Dnepropetrovsk, UA)
Assignee: VECTOR VITALE IP LLC
C07C311/21A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,286,236
App. No.
16/972,169
Granted
Mar 29, 2022
Kind
B2
Abstract

Novel 85 Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.

Claims (34)

1. A compound of the following formula:

wherein each of R 1 through R 14 is independently selected from H, OH, F, Cl, Br, I, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and NO 2 and the 85 Rb e is at least 75% 85 Rb.

2. The compound of claim 1 , wherein the 85 Rb e is at least 90% 85 Rb.

3. The compound of claim 1 wherein R 1 , R 2 , R 4 -R 6 , R 8 , R 10 , R 11 , and R 13 are all H.

4. The compound of claim 3 , wherein the 85 Rb e is at least 90% 85 Rb.

5. The compound of claim 3 wherein R 3 is selected from H, CH 3 , OCH 3 , and NO 2 , R 7 and R 9 are each independently selected from H and OCH 3 , and R 12 and R 14 are each independently selected from H, Br, I, and NO 2 .

6. The compound of claim 5 , wherein the 85 Rb e is at least 90% 85 Rb.

7. The compound of claim 3 , wherein

a) R 3 is CH 3 and R 7 , R 9 , R 12 , and R 14 are all H,

b) R 3 , R 7 , R 9 , R 12 , and R 14 are all H,

c) R 3 is CH 3 , R 14 is Cl, and R 7 , R 9 , and R 12 are all H,

d) R 3 is CH 3 , R 14 is OH and R 7 , R 9 , and R 12 are all H,

e) R 14 is OH and R 3 , R 7 , R 9 , and R 12 are all H,

f) R 3 is OH and R 7 , R 9 , R 12 , and R 14 are all H,

g) R 14 is NO 2 and R 3 , R 7 , R 9 , and R 12 are all H,

h) R 12 is Br, R 14 is NO 2 and R 3 , R 7 , and R 9 are all H,

i) R 3 and R 9 are both OCH 3 , R 12 is Br, R 14 is NO 2 and R 7 is H, or

j) R 3 and R 9 are both OCH 3 , R 14 is NO 2 and R 7 and R 12 are both H.

8. The compound of claim 7 , wherein the 85 Rb e is at least 90% 85 Rb.

9. A composition comprising the compound of claim 1 and an excipient, wherein the compound is present in an amount equivalent to between 40 mg 85 Rb e and 2400 mg 85 Rb e .

10. The composition of claim 9 wherein, in the compound of claim 1 , the 85 Rb e is at least 90% 85 Rb.

11. The composition of claim 10 wherein, in the compound of claim 1 , R 1 , R 2 , R 4 -R 6 , R 8 , R 10 , R 11 , and R 13 are all H.

12. The composition of claim 11 wherein, in the compound of claim 1 , R 3 is selected from H, CH 3 , OCH 3 , and NO 2 , R 7 and R 9 are each independently selected from H and OCH 3 , and R 12 and R 14 are each independently selected from H, Br, I, and NO 2 .

13. The composition of claim 11 , wherein, in the compound of claim 1 ,

a) R 3 is CH 3 and R 7 , R 9 , R 12 , and R 14 are all H,

b) R 3 , R 7 , R 9 , R 12 , and R 14 are all H,

c) R 3 is CH 3 , R 14 is Cl, and R 7 , R 9 , and R 12 are all H,

d) R 3 is CH 3 , R 14 is OH and R 7 , R 9 , and R 12 are all H,

e) R 14 is OH and R 3 , R 7 , R 9 , and R 12 are all H,

f) R 3 is OH and R 7 , R 9 , R 12 , and R 14 are all H,

g) R 14 is NO 2 and R 3 , R 7 , R 9 , and R 12 are all H,

h) R 12 is Br, R 14 is NO 2 and R 3 , R 7 , and R 9 are all H,

i) R 3 and R 9 are both OCH 3 , R 12 is Br, R 14 is NO 2 and R 7 is H, or

j) R 3 and R 9 are both OCH 3 , R 14 is NO 2 and R 7 and R 12 are both H.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2021
From: NOVAK, PETER; TEMNIKOV, MAX
To: VECTOR VITALE IP LLC
Reel/Frame 057837/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2021
From: BALAKIN, OLEKSANDR
To: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
Reel/Frame 055921/0550 →
Continuity (3)
Provisional Application 62741318 · Oct 4, 2018
Provisional Application 62680584 · Jun 5, 2018
Related Publication 20210246104A1 · Aug 12, 2021